(2)
Due to the pandemic, the Annual General Meeting of Roche Holding Ltd will take place on 16 March 2021 without the physical presence of shareholders and with only the persons required by the Articles of Incorporation in attendance
During the Annual General Meeting, shareholders rights will be exercised exclusively via the independent proxy, without the physical presence of shareholders
Basel, 18 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that unfortunately it will not be possible for shareholders to attend the Annual General Meeting in person owing to the ongoing pandemic. Our main concern is to protect our shareholders from any potential health risks that may arise because of the ongoing difficult pandemic situation.
唱歌，写诗，做木工…想得诺贝尔奖必须多才多艺？ 163.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 163.com Daily Mail and Mail on Sunday newspapers.
F. Hoffmann-La Roche Ltd: Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer
19.2
6.9
18.1
Tecentriq + Avastin (n=133)
24.0
(0.35-0.80)
Median follow-up: 15.6 months.
CR, complete response; DOR, duration of response; HR, hazard ratio; NE, not estimable; ORR, objective response rate; OS, overall survival; PFS, progression free response; PR, partial response; SD, stable disease.
See below for OS data from the primary analysis.
About the IMbrave150 study
IMbrave150 is a global Phase III, multicentre, open-label study of 501 people with unresectable HCC who had not received prior systemic therapy. People were randomised 2:1 to receive the combination of Tecentriq and Avastin or sorafenib. Tecentriq was administered intravenously (IV), 1200 mg on day 1 of each 21-day cycle, and Avastin was administered IV, 15 mg/kg on day 1 of each 21-day cycle. Sorafenib wa
(2)
uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis aid pathologists in providing faster, more accurate patient diagnoses in breast cancer
In combination with the VENTANA DP 200 slide scanner and Roche uPath enterprise software, the new algorithms provide innovative digital pathology solutions to advance personalised healthcare
Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year. About 15 to 20 percent of women diagnosed with breast cancer are HER2 positive
Basel, 11 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine the best treatment strategy for each patient. The image analysis algorithms use artificial intelligence to support pathologists in making faster, more accurate patient diagnoses in breast cancer.
(2)
The European Commission (EC) has approved single-dose, oral Xofluza for the treatment of uncomplicated influenza in patients aged 12 years and above
The EC has also approved Xofluza for post-exposure prophylaxis of influenza in individuals aged 12 years and above
Xofluza, with its rapid reduction in viral replication, could help patients recover more quickly, while also reducing the societal burden of influenza
Basel, 11 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has approved Xofluza (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged 12 years and above. In addition, the EC has approved Xofluza for post-exposure prophylaxis of influenza in individuals aged 12 years and above. Post-exposure prophylaxis aims to prevent influenza in individuals following contact with someone infected with the influenza virus. The Commission s Decision follows the positive opinion received from the European Me